Ethris nasal mRNA therapy cuts rhinovirus load 40-fold in asthma trial

manilatimes.net —

German biotech company Ethris announced positive Phase 2a trial results for ETH47, a nasal mRNA therapeutic for asthma patients, showing a 40-fold reduction in rhinovirus load versus placebo at peak viral replication on Day 2. The single-dose treatment was safe and well tolerated, demonstrating consistent clinical improvements including reduced lower respiratory symptoms, fewer mild exacerbations, and lower rescue medication use compared to placebo. Higher interferon lambda exposure correlated with greater antiviral and clinical effects. Ethris plans further studies including a multiple-dose trial in asthma and COPD patients, a COPD challenge study, and Phase 2b field trials. The company is also developing a dry powder formulation for room-temperature stability.


With a significance score of 3.4, this news ranks in the top 9% of today's 32483 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Ethris nasal mRNA therapy cuts rhinovirus load 40-fold in asthma trial | News Minimalist